Alyeska Investment Group
RNAC icon

Alyeska Investment Group’s Cartesian Therapeutics RNAC Stock Holding History

Alyeska Investment Group’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,382
Closed -$2.3M – 535
2016
Q3 		$2.3M Sell
5,382
-451
-8% -$176K 0.02% 378
2016
Q2 		$2.45M Buy
+5,833
New +$2.45M 0.02% 356

Other funds holding RNAC

PVMCV
Polaris Venture Management Co V Boston, Massachusetts $14.1M AUM 121.41% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
SRF
Silver Rock Financial Los Angeles, California $49.7M AUM 17.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Alyeska Investment Group's RNAC Position: Q4 2016 in Review

Alyeska Investment Group sold out of Cartesian Therapeutics (RNAC) in Q4 2016, closing a stake of 5,382 shares — an estimated $2.3M sold.

Alyeska Investment Group first reported a position in RNAC in Q2 2016 and held it in 2 quarters. The position peaked at $2.45M in Q2 2016. 43 funds tracked by Wall St. Rank hold RNAC as of Q4 2016.

  • Alyeska Investment Group reported no remaining Cartesian Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Alyeska Investment Group sold 5,382 Cartesian Therapeutics shares in Q4 2016, an estimated $2.3M.
  • Alyeska Investment Group first reported a position in Cartesian Therapeutics in Q2 2016 and held it in 2 quarters.
  • Alyeska Investment Group's Cartesian Therapeutics position peaked at $2.45M in Q2 2016.
  • 43 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q4 2016.

Based on Alyeska Investment Group's 13F filing for Q4 2016, filed 14 Feb 2017.